MicroRNAs Associated with Chronic Kidney Disease in the General Population and High-risk Subgroups: Protocol for a Systematic Review and Meta-analysis

Overview

Journal BMJ Open

Specialty General Medicine

Date 2022 Feb 17

PMID 35173010

Authors

Dipuo Dephney Motshwari

Don Makwakiwe Matshazi

Rajiv Erasmus

A P Kengne

Tandi E Matsha

Cindy George

Affiliations

Soon will be listed here.

Abstract

Introduction: Chronic kidney disease (CKD) is a significant health and economic burden, owing to its ever-increasing global prevalence. Due to the limitations in the current diagnostic methods, CKD is frequently diagnosed at advanced stages, where there is an increased risk of cardiovascular complications and end-stage kidney disease. As such, there has been considerable interest in microRNAs (miRNAs) as potential markers for CKD detection. This review seeks to identify all miRNAs associated with CKD and/or markers of kidney function or kidney damage in the general population and high-risk subgroups, and explore their expression profiles in these populations.

Methods And Analysis: A systematic search of published literature will be conducted for observational studies that report on miRNAs associated with CKD or kidney function or kidney damage markers (serum creatinine and cystatin C, estimated glomerular filtration rate and urinary albumin excretion) in adult humans. The electronic database search will be restricted to English and French publications up to 31 October 2021. Two investigators will independently screen and identify studies for inclusion, as well as extract data from eligible studies. Risk-of-bias and methodological quality will be assessed by the Newcastle-Ottawa Quality Assessment Scale for observational studies and Grading of Recommendations Assessment, Development and Evaluation tools. Appropriate meta-analytic techniques will be used to pool estimates from studies with similar miRNAs, overall and by major characteristics, including by country or region, sample size, gender and risk-of-bias score. Heterogeneity of the estimates across studies will be quantified and publication bias investigated. This protocol is reported according to Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols 2015 guidelines.

Ethics And Dissemination: This study design does not require formal ethical clearance and findings will be published in a peer-reviewed journal.

Conclusion: This review will provide the expression pattern of miRNAs associated with CKD. This will allow for further research into the identified miRNAs, which could later be used as biomarkers for prediction and early detection of CKD, monitoring of disease progression to advanced stages and as potential therapeutic targets.

Prospero Registration Number: CRD42021270028.

Citing Articles

MicroRNAs Associated with Chronic Kidney Disease in the General Population and High-Risk Subgroups-A Systematic Review.

Motshwari D, Matshazi D, Erasmus R, Kengne A, Matsha T, George C Int J Mol Sci. 2023; 24(2).

PMID: 36675311 PMC: 9863068. DOI: 10.3390/ijms24021792.

References

Rysz J, Gluba-Brzozka A, Franczyk B, Jablonowski Z, Cialkowska-Rysz A . Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome. Int J Mol Sci. 2017; 18(8). PMC: 5578092. DOI: 10.3390/ijms18081702. View

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

Chandrasekaran K, Karolina D, Sepramaniam S, Armugam A, Wintour E, Bertram J . Role of microRNAs in kidney homeostasis and disease. Kidney Int. 2012; 81(7):617-27. DOI: 10.1038/ki.2011.448. View

Fourdinier O, Schepers E, Metzinger-Le Meuth V, Glorieux G, Liabeuf S, Verbeke F . Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients. Sci Rep. 2019; 9(1):4477. PMC: 6418179. DOI: 10.1038/s41598-019-41101-8. View

Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S . Cause of Death in Patients with Reduced Kidney Function. J Am Soc Nephrol. 2015; 26(10):2504-11. PMC: 4587695. DOI: 10.1681/ASN.2014070714. View

Bansal N, Katz R, Robinson-Cohen C, Odden M, Dalrymple L, Shlipak M . Absolute Rates of Heart Failure, Coronary Heart Disease, and Stroke in Chronic Kidney Disease: An Analysis of 3 Community-Based Cohort Studies. JAMA Cardiol. 2016; 2(3):314-318. PMC: 5832350. DOI: 10.1001/jamacardio.2016.4652. View

Andrassy K . Comments on 'KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease'. Kidney Int. 2013; 84(3):622-3. DOI: 10.1038/ki.2013.243. View

Mitchell P, Parkin R, Kroh E, Fritz B, Wyman S, Pogosova-Agadjanyan E . Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105(30):10513-8. PMC: 2492472. DOI: 10.1073/pnas.0804549105. View

Bonneau E, Neveu B, Kostantin E, Tsongalis G, De Guire V . How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market. EJIFCC. 2019; 30(2):114-127. PMC: 6599191. View

10.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

11.

Wonnacott A, Bowen T, Fraser D . MicroRNAs as biomarkers in chronic kidney disease. Curr Opin Nephrol Hypertens. 2017; 26(6):460-466. DOI: 10.1097/MNH.0000000000000356. View

12.

Carney E . The impact of chronic kidney disease on global health. Nat Rev Nephrol. 2020; 16(5):251. DOI: 10.1038/s41581-020-0268-7. View

13.

Londin E, Loher P, Telonis A, Quann K, Clark P, Jing Y . Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proc Natl Acad Sci U S A. 2015; 112(10):E1106-15. PMC: 4364231. DOI: 10.1073/pnas.1420955112. View

14.

Wang X, Liu R, Zhang W, Hyink D, Das G, Das B . Role of SIRT1 in HIV-associated kidney disease. Am J Physiol Renal Physiol. 2020; 319(2):F335-F344. PMC: 7473906. DOI: 10.1152/ajprenal.00140.2020. View

15.

. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020; 395(10225):709-733. PMC: 7049905. DOI: 10.1016/S0140-6736(20)30045-3. View

16.

Bartel D . MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2):215-33. PMC: 3794896. DOI: 10.1016/j.cell.2009.01.002. View

17.

Al-Rubeaan K, Siddiqui K, Al-Ghonaim M, Youssef A, Al-Sharqawi A, Alnaqeb D . Assessment of the diagnostic value of different biomarkers in relation to various stages of diabetic nephropathy in type 2 diabetic patients. Sci Rep. 2017; 7(1):2684. PMC: 5457399. DOI: 10.1038/s41598-017-02421-9. View

18.

Sun Y, Koo S, White N, Peralta E, Esau C, Dean N . Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res. 2004; 32(22):e188. PMC: 545483. DOI: 10.1093/nar/gnh186. View

19.

Wang L, Gao Y, Song B, Yu G, Chen H, Zhang Z . MicroRNAs in the Progress of Diabetic Nephropathy: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med. 2019; 2019:3513179. PMC: 6431481. DOI: 10.1155/2019/3513179. View

20.

Fujii R, Yamada H, Yamazaki M, Munetsuna E, Ando Y, Ohashi K . Circulating microRNAs (miR-126, miR-197, and miR-223) are associated with chronic kidney disease among elderly survivors of the Great East Japan Earthquake. BMC Nephrol. 2019; 20(1):474. PMC: 6925484. DOI: 10.1186/s12882-019-1651-0. View